Sight Sciences, Inc. is introducing a new addition to its OMNI product line: the OMNI Edge Surgical System for minimally invasive glaucoma surgery (MIGS).
The system’s unveiling coincides with the 2025 annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS), April 25-27, in Los Angeles, California.
Why don’t we start with this OMNI line.
The company’s OMNI product family was first introduced in 2018 with the FDA’s clearance of the original OMNI Surgical System.
About that system: Following its initial clearance, the OMNI was dually indicated for the delivery of controlled volumes of viscoelastic fluid during ophthalmic surgery as well as cutting of trabecular meshwork (TM) tissue during trabeculotomy procedures.
- See here for how it works.
Fast forward to 2021: The system became the first (and only) implant-free, single-use ab interno glaucoma device indicated for canaloplasty followed by trabeculotomy to reduce intraocular pressure (IOP).
- Its target patients: Adults with primary open-angle glaucoma (POAG).
And wasn’t there another new addition after that?
Indeed there was. In March 2023, the company launched the Ergo-Series for its OMNI Surgical System.
The highlights: This new design built on the original system with three new features enabling improved ergonomic function and precise access.
Got it. So how does OMNI Edge compare to the original system?
Similar to the OMNI, this hand-held and single-use therapeutic device can be used as a versatile and implant-free MIGS standalone procedure—or in combination with cataract surgery.
Its purpose: As with the OMNI, it’s designed to reduce IOP by giving surgeons 360° of customized access to target and treating all three known areas of resistances (see below) in the aqueous outflow system via a single clear corneal microincision:
- Schlemm’s canal
- TM
- Collector channels
Notably: The OMNI Edge is also adaptable for all POAG stages.
Any unique technology incorporated in it?
Yes! While the system retains the intuitive design and performance of the OMNI, it also features Sight Sciences’ patented, higher-capacity viscoelastic delivery TruSync technology.
About TruSync: This synchronizes with a surgeon’s rotation of the control wheel to allow for “consistent, predictable, and reproducible viscoelastic deployment along every clock hour of Schlemm’s canal that is treated.”
- Plus: The device’s higher-capacity capabilities enable it to precisely control and deliver up to 21 µL—nearly twice that of the original OMNI’s 11 µL capacity.
And what viscoelastics can it be used with?
Only those that are commercially available within the United States, according to the device’s downloadable instructions for use.
Such examples include:
- Healon PRO or Healon GV PRO ( Johnson & Johnson Vision)
- Amvisc (Bausch + Lomb)
- PROVISC (Alcon)
Notably: The device is only indicated for use with cohesive viscoelastic fluid; it’s not advised for use with dispersive viscoelastic fluid or visco-adaptive fluids.
Let’s talk supporting clinical data.
The OMNI Edge is backed by clinical findings from the multi-center, retrospective, observational ROMEO study of 129 pseudophakic OAG patients (aged 45+) treated with the OMNI Surgical System as a standalone procedure or with cataract surgery.
- The gist of those findings: A combination of canaloplasty followed by trabeculotomy (as stand-alone procedures) with the OMNI system provided effective IOP reduction, sustained IOP control, and a meaningful reduction for up to 12 months postoperatively.
- And see here for promising 2-year data on an extension of that study.
Anything more recently?
In January 2025, Sight Sciences released real-world findings on the OMNI system using data from the American Academy of Ophthalmology (AAO) Intelligent Research in Sight (IRS) Registry.
- Those findings: The OMNI system as a standalone procedure demonstrated continued effectiveness with either IOP or medication reductions over time for the majority of patients—particularly those with lower baseline IOP.
- The crux of this: The data supported the OMNI system’s long-term efficacy in sustaining reduced IOP and medication use.
Nice! So any warnings or precautions to keep in mind when using it?
A few contraindications have been noted, in which the OMNI Edge shouldn’t be used:
- In any situations where the iridocorneal angle is compromised or damaged
- With angle recession; neovascular glaucoma; chronic angle closure; narrow-angle glaucoma; traumatic or malignant glaucoma; or narrow inlets canals with plateau iris
- In quadrants with previous MIGS implants
How about potential adverse events?
Included among those that “may be reasonably associated” with the use of the OMNI system in the eye:
- Anterior chamber shallowing
- Severe, prolonged, or persistent intraocular inflammation
- Endophthalmitis or other ocular infection
- Aqueous misdirection
- Descemet’s membrane tear or detachment
- Intracorneal hematoma
See here for more (under “important product information”).
Good to know. So where can I get a look at this new device?
If you’re attending ASCRS, attendees are invited to stop by the Sight Sciences booth (#2439) on April 26 (4 to 5 p.m. PST) and celebrate the product launch.
- Click here to RSVP for that event.
And as a bonus: Check out (and RSVP for) seven other events the company is hosting during the annual meeting.